Vertex Pharma (VRTX) – Globe Newswire
-
Vortex Energy Corp. Sends Core Samples from the Robinsons River Salt Project to the University of Alberta
-
Vortex Energy Announces Drilling Update and $115,500 Grant Award At The Robinsons River Salt Project
-
Vortex Energy Closes Charity Flow-Through Private Placement for Gross Proceeds of C$830,000
-
Vortex Energy Corp. Provides Update on Drilling at the Robinsons River Salt Project
-
Vortex Energy Announces Further Extension of Marketing Campaign
-
Vortex Energy Announces the Recommencement of its Drilling Program at the Robinsons River Salt Project, Newfoundland & Labrador
-
Vortex Energy Announces Results of Shareholder Meeting
-
Vortex Energy Commences Drill Trail Clearing Process at the Robinsons River Salt Project, Newfoundland & Labrador
-
Vortex Energy Re-Mobilizes for Exploration Program at the Robinsons River Salt Project
-
Vortex Energy Announces Uplisting on the OTCQB
-
Vortex Energy Intersects Salt On The Western Salt Structure At The Robinsons River Salt Project
-
Vortex Energy Announces Commencement of Drilling Program at Robinsons River Salt Project, Newfoundland & Labrador
-
Vortex Energy Clears Drill Trail and Completes Earthworks for Drilling Pads at the Robinsons River Salt Project, Newfoundland & Labrador
-
Vortex Energy Announces Further Extension of Marketing Campaign
-
Vortex Energy Commences Mobilization for Fall Exploration Program at the Robinsons River Salt Project
-
Vortex Energy Selects Wireline Survey Contractor for Exploration Program at the Robinsons River Salt Project
-
Vortex Energy Announces Extension of Marketing Program
-
Vortex Energy Selects Drill Contractor for Exploration Program at the Robinsons River Salt Project
-
Vortex Energy Diamond Core Drilling Application Approved For Exploration At The Robinsons River Salt Project
-
Vortex Energy Partners with the University of Alberta on Collaborative Research on Hydrogen and Energy Storage at the Robinsons River Salt Project
-
Vortex Energy Submits Diamond Drilling Application For Exploration Approval For The Robinsons River Salt Project
-
Vortex Energy Announces Further Extension of Marketing Campaign
-
Vortex Energy Announces Its 2023 Fall Program on Its Robinsons River Salt Project
-
Vortex Energy Closes Purchase of Additional Mineral License in Newfoundland
-
Vortex Energy Announces Large Scale Hydrogen Storage Estimates at the Robinsons River Salt Project
-
Vortex Energy Announces Further Extension of Marketing Campaign
-
Vortex Energy enters into Agreement to Acquire Additional Mineral License in Newfoundland
-
Vortex Energy Unaware of any Material Change
-
Vortex Energy Announces Extension of Marketing Campaign
-
Vortex Energy Unveils 3D Geology Model of the Robinsons River Salt Dome Property
-
Vortex Energy Appoints the Honourable George J. Furey as an Advisor and Grants Options
-
Vortex Energy Identifies At Least Two Salt Structures Suitable for Hydrogen Storage
-
Vortex Energy Completes Seismic Interpretation
-
Vortex Energy Congratulates World Energy GH2 for Receiving International Investment
-
Vortex Engages RESPEC to Advance its Robinsons River Salt Project in Newfoundland & Labrador, CANADA
-
Vortex Engages Independent Trading Group as Market Maker
-
Vortex Energy Announces the Addition of Strategic Advisors & Options Issuance
-
Vortex Energy Announces the Addition of Shawn Ryan as Technical Advisor
-
Vortex Energy Completes Acquisition of Blue Ocean Salt Corp.
-
Vortex Energy Corp. Announces Appointment of Paul Sparkes as Chief Executive Officer & Director
-
Vortex Energy Corp. Announces Letter Agreement for Acquisition of Blue Ocean Salt Corp.
-
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
-
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
-
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
-
Catalyst Biosciences Sells Complement Portfolio for $60 Million
-
Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
-
OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer
-
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Vi
-
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
-
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
Back to VRTX Stock Lookup
